Gunnar Juliusson
131 – 140 of 159
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
- Contribution to journal › Article
-
Mark
Bendamustine in the Treatment of Chronic Lymphocytic Leukemia - Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups
- Contribution to journal › Published meeting abstract
-
Mark
Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse
- Contribution to journal › Published meeting abstract
-
Mark
Mechanisms of anti-cancer action and pharmacology of clofarabine
- Contribution to journal › Debate/Note/Editorial
-
Mark
Bendamustine versus chlorambucil in treatment- naive patients with chronic lymphocytic leukemia: Updated results of an international phase III study
(2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0355-0355
- Contribution to journal › Published meeting abstract
-
Mark
LPL Is the Strongest Prognostic Factor in a Comparative Study of RNA-Based Markers in Chronic Lymphocytic Leukemia
- Contribution to journal › Published meeting abstract
-
Mark
High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
- Contribution to journal › Article
-
Mark
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia.
- Contribution to journal › Article
- 2008
-
Mark
Screening For Copy-Number Alterations And Loss-Of-Heterozygosity In Chronic Lymphocytic Leukemia - A Comparative Study Of Four Differently Designed, High Resolution Microarray Platforms
(2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0536-0536
- Contribution to journal › Published meeting abstract
-
Mark
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma - Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone
- Contribution to journal › Article
